Use of eltrombopag after romiplostim in primary immune thrombocytopenia

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

(2013) G. D'Arena et al.   BLOOD

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

(2013) M. Khellaf et al.   HAEMATOLOGICA

Highly Fluctuating Thrombocytopenia Developing in a Patient with Immune Thrombocytopenia (ITP) while Administering Romiplostim

(2012) Kenji Shinohara et al.   INTERNAL MEDICINE

Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations

(2012) T. Aoki et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

(2011) M. Khellaf et al.   BLOOD

New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura

(2010) David J. Kuter   EUROPEAN JOURNAL OF HAEMATOLOGY

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Novel Thrombopoietic Agents

(2008) Roberto Stasi et al.   DRUGS

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET